Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy
Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy
A new era of early cancer detection with blood test may change cancer screening paradigms
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC
Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy
Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma
Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma
Hyperthermic intraperitoneal chemo for locally advanced colon cancer
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan
Lasofoxifene shows promise for women with ESR1-mutated mBC
New data presented at ESMO for multi-cancer early detection